The latest report adds a patient count to a clinical program whose first implantation took place on October 29, 2025. That earlier date matters: the new development is progress in the trial, rather than the first operation occurring in October 2026.
Donor Cells Become Laboratory Tissue
Precise Bio's approach starts with human corneal cells, which are cultivated and organized into an implant through biological printing. In its original clinical announcement, the company described a robotic manufacturing process designed to produce a precisely layered structure for transplantation.
The implant, called PB-001, is intended to reproduce important properties of corneal tissue. The company says its production method combines cell biology, biomaterials and tissue engineering. The cornea remains the first clinical focus, rather than evidence that the same platform already supplies other replacement organs.
The First Procedure Established the Starting Point
Precise Bio announced the initial human implantation on November 19, 2025. Its statement said the procedure had been performed at Rambam on October 29, under the leadership of Professor Michael Mimouni, director of the hospital's Cornea Unit.
That announcement described a patient who was legally blind before receiving the implant in one eye. The October 22 TPS report, citing the company, says the first patient regained vision in the treated eye. It does not report equivalent visual outcomes for each of the other four recipients.
Five Recipients Within an Early Clinical Study
The company's original study design called for approximately ten to fifteen participants with corneal edema caused by endothelial dysfunction. Precise Bio described a Phase 1 study primarily examining safety and tolerability, with early measures of effectiveness also being explored.
The trial has a single treatment group, without a separate control group. That design makes the current work an initial clinical evaluation. The five reported implantations demonstrate that the program has advanced beyond its first participant; larger studies and continued follow up would be needed to establish broader clinical performance.
The original protocol also included an exploratory assessment of effectiveness at six months. The company describes optical clarity and mechanical properties as design objectives for the implant; those objectives are among the reasons clinical observation matters alongside the ability to manufacture the tissue.
A Manufacturing Answer to Donor Scarcity
Founder Aryeh Batt told TPS that one donor could potentially provide cells for hundreds of implants. The proposed benefit is the ability to expand a limited biological starting material into a repeatable tissue product, rather than relying on one donor cornea for each graft.
In its earlier statement, Precise Bio said the implant is manufactured at its facility at Sheba Medical Center. The company described isolating, cultivating and printing corneal cells there, while Rambam serves as the clinical site. Those are different roles within the same development program.
TPS also reported the company's ambition to develop additional tissues and eventually parts of organs such as hearts, livers and kidneys. Those remain development goals. The immediate clinical milestone is narrower and tangible: five people have now received the experimental corneal tissue, with the study examining how it performs in the human eye.
